Evolent Health, Inc. (NYSE:EVH – Free Report) – Equities research analysts at William Blair dropped their Q4 2024 earnings estimates for Evolent Health in a report issued on Thursday, January 30th. William Blair analyst R. Daniels now anticipates that the technology company will earn ($0.06) per share for the quarter, down from their prior estimate of ($0.05). The consensus estimate for Evolent Health’s current full-year earnings is $0.24 per share.
Evolent Health (NYSE:EVH – Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The technology company reported ($0.08) EPS for the quarter, missing the consensus estimate of $0.30 by ($0.38). Evolent Health had a positive return on equity of 6.30% and a negative net margin of 2.93%. The company had revenue of $621.40 million during the quarter, compared to analysts’ expectations of $625.58 million. During the same quarter last year, the company earned $0.19 earnings per share.
Evolent Health Stock Performance
Shares of EVH opened at $10.27 on Monday. The business has a 50-day simple moving average of $11.22 and a two-hundred day simple moving average of $19.91. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. Evolent Health has a 52 week low of $9.74 and a 52 week high of $35.00. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -11.28 and a beta of 1.45.
Institutional Investors Weigh In On Evolent Health
Several large investors have recently bought and sold shares of EVH. Royce & Associates LP bought a new stake in shares of Evolent Health in the 3rd quarter valued at approximately $7,070,000. Foundry Partners LLC bought a new stake in Evolent Health in the third quarter worth $10,042,000. Salem Investment Counselors Inc. boosted its stake in Evolent Health by 53.0% during the fourth quarter. Salem Investment Counselors Inc. now owns 350,155 shares of the technology company’s stock worth $3,939,000 after buying an additional 121,369 shares during the period. Harbor Capital Advisors Inc. increased its position in Evolent Health by 140.0% during the third quarter. Harbor Capital Advisors Inc. now owns 422,421 shares of the technology company’s stock valued at $11,946,000 after acquiring an additional 246,400 shares during the last quarter. Finally, Nordea Investment Management AB raised its stake in shares of Evolent Health by 7.0% in the fourth quarter. Nordea Investment Management AB now owns 130,453 shares of the technology company’s stock valued at $1,469,000 after acquiring an additional 8,552 shares during the period.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
See Also
- Five stocks we like better than Evolent Health
- Buy P&G Now, Before It Sets A New All-Time High
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Why Are These Companies Considered Blue Chips?
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.